HIV surveillance among injecting drug users

Don Des Jarlais, Karl Dehne, Jordi Casabona

Research output: Contribution to journalArticle

Abstract

Injecting drug users (IDUs) should be considered a 'partially hidden population' at high risk for HIV infection. In almost all locations it should be possible to locate and conduct research with IDUs, but it will probably never be possible to enumerate or draw random samples from an IDU population. Surveillance research studies with IDUs should include risk behaviors, as surveillance of HIV infection only will not be sufficiently time sensitive, and be used to develop and refine HIV prevention programming for the population. Contacts with IDUs can be developed at multiple settings, including voluntary treatment programs, law enforcement settings, and through 'street outreach.' Each type of setting has different advantages, disadvantages and ethical concerns. HIV testing as part of surveillance also raises additional important ethical concerns. The primary risk behaviors that should be included in surveillance studies are 'sharing' of drug injection equipment, the potential for rapid partner change among risk partners, and sexual risk behavior. Additional important objectives for surveillance research include: (1) the size of the local IDU population, (2) patterns of drug use, (3) availability injection equipment, (4) participation in prevention activities, and (5) access to and use of anti-retroviral treatments. HIV incidence is an ultimate objective for surveillance research, but there are no currently available cost-efficient methods for studying HIV incidence, so estimation from indirect measurements is usually required.

Original languageEnglish (US)
JournalAIDS
Volume15
Issue numberSUPPL. 3
DOIs
StatePublished - May 25 2001

Fingerprint

Drug Users
HIV
Risk-Taking
Research
HIV Infections
Voluntary Programs
Population
Law Enforcement
Equipment and Supplies
Injections
Incidence
Sexual Behavior
Pharmaceutical Preparations
Costs and Cost Analysis
Therapeutics

Keywords

  • AIDS
  • Behavior
  • HIV
  • Injecting drug use
  • Substance abuse
  • Surveillance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

HIV surveillance among injecting drug users. / Des Jarlais, Don; Dehne, Karl; Casabona, Jordi.

In: AIDS, Vol. 15, No. SUPPL. 3, 25.05.2001.

Research output: Contribution to journalArticle

Des Jarlais, Don ; Dehne, Karl ; Casabona, Jordi. / HIV surveillance among injecting drug users. In: AIDS. 2001 ; Vol. 15, No. SUPPL. 3.
@article{bd5b132d0e8e467daaef0aa423fe99a4,
title = "HIV surveillance among injecting drug users",
abstract = "Injecting drug users (IDUs) should be considered a 'partially hidden population' at high risk for HIV infection. In almost all locations it should be possible to locate and conduct research with IDUs, but it will probably never be possible to enumerate or draw random samples from an IDU population. Surveillance research studies with IDUs should include risk behaviors, as surveillance of HIV infection only will not be sufficiently time sensitive, and be used to develop and refine HIV prevention programming for the population. Contacts with IDUs can be developed at multiple settings, including voluntary treatment programs, law enforcement settings, and through 'street outreach.' Each type of setting has different advantages, disadvantages and ethical concerns. HIV testing as part of surveillance also raises additional important ethical concerns. The primary risk behaviors that should be included in surveillance studies are 'sharing' of drug injection equipment, the potential for rapid partner change among risk partners, and sexual risk behavior. Additional important objectives for surveillance research include: (1) the size of the local IDU population, (2) patterns of drug use, (3) availability injection equipment, (4) participation in prevention activities, and (5) access to and use of anti-retroviral treatments. HIV incidence is an ultimate objective for surveillance research, but there are no currently available cost-efficient methods for studying HIV incidence, so estimation from indirect measurements is usually required.",
keywords = "AIDS, Behavior, HIV, Injecting drug use, Substance abuse, Surveillance",
author = "{Des Jarlais}, Don and Karl Dehne and Jordi Casabona",
year = "2001",
month = "5",
day = "25",
doi = "10.1097/00002030-200104003-00003",
language = "English (US)",
volume = "15",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 3",

}

TY - JOUR

T1 - HIV surveillance among injecting drug users

AU - Des Jarlais, Don

AU - Dehne, Karl

AU - Casabona, Jordi

PY - 2001/5/25

Y1 - 2001/5/25

N2 - Injecting drug users (IDUs) should be considered a 'partially hidden population' at high risk for HIV infection. In almost all locations it should be possible to locate and conduct research with IDUs, but it will probably never be possible to enumerate or draw random samples from an IDU population. Surveillance research studies with IDUs should include risk behaviors, as surveillance of HIV infection only will not be sufficiently time sensitive, and be used to develop and refine HIV prevention programming for the population. Contacts with IDUs can be developed at multiple settings, including voluntary treatment programs, law enforcement settings, and through 'street outreach.' Each type of setting has different advantages, disadvantages and ethical concerns. HIV testing as part of surveillance also raises additional important ethical concerns. The primary risk behaviors that should be included in surveillance studies are 'sharing' of drug injection equipment, the potential for rapid partner change among risk partners, and sexual risk behavior. Additional important objectives for surveillance research include: (1) the size of the local IDU population, (2) patterns of drug use, (3) availability injection equipment, (4) participation in prevention activities, and (5) access to and use of anti-retroviral treatments. HIV incidence is an ultimate objective for surveillance research, but there are no currently available cost-efficient methods for studying HIV incidence, so estimation from indirect measurements is usually required.

AB - Injecting drug users (IDUs) should be considered a 'partially hidden population' at high risk for HIV infection. In almost all locations it should be possible to locate and conduct research with IDUs, but it will probably never be possible to enumerate or draw random samples from an IDU population. Surveillance research studies with IDUs should include risk behaviors, as surveillance of HIV infection only will not be sufficiently time sensitive, and be used to develop and refine HIV prevention programming for the population. Contacts with IDUs can be developed at multiple settings, including voluntary treatment programs, law enforcement settings, and through 'street outreach.' Each type of setting has different advantages, disadvantages and ethical concerns. HIV testing as part of surveillance also raises additional important ethical concerns. The primary risk behaviors that should be included in surveillance studies are 'sharing' of drug injection equipment, the potential for rapid partner change among risk partners, and sexual risk behavior. Additional important objectives for surveillance research include: (1) the size of the local IDU population, (2) patterns of drug use, (3) availability injection equipment, (4) participation in prevention activities, and (5) access to and use of anti-retroviral treatments. HIV incidence is an ultimate objective for surveillance research, but there are no currently available cost-efficient methods for studying HIV incidence, so estimation from indirect measurements is usually required.

KW - AIDS

KW - Behavior

KW - HIV

KW - Injecting drug use

KW - Substance abuse

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=0035947155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035947155&partnerID=8YFLogxK

U2 - 10.1097/00002030-200104003-00003

DO - 10.1097/00002030-200104003-00003

M3 - Article

VL - 15

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - SUPPL. 3

ER -